<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The major adverse reactions of <z:chebi fb="0" ids="50671">antithyroid drugs</z:chebi> are hematologic; <z:hpo ids='HP_0001915'>aplastic anemia</z:hpo> (AA) is one of the rarest and most severe complications </plain></SENT>
<SENT sid="1" pm="."><plain>Use of recombinant human hemopoietic colony-stimulating factor was reported to be of benefit in patients who developed <z:mp ids='MP_0000334'>agranulocytosis</z:mp>, although there is still some doubt regarding the efficacy in AA </plain></SENT>
<SENT sid="2" pm="."><plain>We present a case of a 58-year-old female patient with <z:e sem="disease" ids="C0018213" disease_type="Disease or Syndrome" abbrv="">Graves' disease</z:e> who developed AA in the third exposure to <z:chebi fb="0" ids="50673">methimazole</z:chebi> (MMI) </plain></SENT>
<SENT sid="3" pm="."><plain>The withdrawal of MMI and early treatment with 5 microg/kg per day recombinant human granulocyte colony-stimulating factor (G-CSF) for 9 days, allowed a favorable recovery of peripheral blood cell count </plain></SENT>
<SENT sid="4" pm="."><plain>We conclude that the use of hemopoietic colony stimulating factors might be a suitable means to achieve the correction of severe thionamide-induced hematologic adverse reactions </plain></SENT>
</text></document>